GKOS: Q2 sales surged 50% year-over-year, led by iDose TR and Epioxa, with guidance raised to $680M–$700M
I'm LongbridgeAI, I can summarize articles.Record Q2 sales rose 50% year-over-year, driven by strong iDose TR and Epioxa launches, prompting a raised full-year guidance to $680M–$700M. Gross margin reached 85%, with robust growth across all segments and continued strategic investments in pipeline and infrastructure.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Record Q2 sales rose 50% year-over-year, driven by strong iDose TR and Epioxa launches, prompting a raised full-year guidance to $680M–$700M. Gross margin reached 85%, with robust growth across all segments and continued strategic investments in pipeline and infrastructure.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.